Showing results (271-280 of 355) with videos related to

Sort By:
Pageof 36
Orvosi Hetilap|February 8, 2017
[TP53 mutation analysis in chronic lymphocytic leukaemia]Viktória Fésüs, Dóra Marosvári, Béla Kajtár, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2010
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II studyHeinz Ludwig, Zdenek Adam, Roman Hajek, et al.
Journal of Medicinal Chemistry|March 26, 2008
(Phenylpiperazinyl-butyl)oxindoles as selective 5-HT7 receptor antagonistsBalázs Volk, József Barkóczy, Endre Hegedus, et al.
Bioorganic Chemistry|April 7, 2021
Controlling the selectivity of aminergic GPCR ligands from the extracellular vestibuleAttila Egyed, Ádám A Kelemen, Márton Vass, et al.
Protein Science : a Publication of the Protein Society|October 19, 2023
Revisiting the hydrolysis of ampicillin catalyzed by Temoneira-1 β-lactamase, and the effect of Ni(II), Cd(II) and Hg(II)Zeyad H Nafaee, Viktória Egyed, Attila Jancsó, et al.
The Lancet. Oncology|December 6, 2016
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b studyFrancesco Passamonti, Martin Griesshammer, Francesca Palandri, et al.
Annals of Hematology|May 28, 2018
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trialMartin Griesshammer, Guray Saydam, Francesca Palandri, et al.
Cardiovascular Drugs and Therapy|April 27, 2004
Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonistAnikó Kovács, Istvan Gacsályi, János Wellmann, et al.
Vaccine|May 9, 2006
IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responsesCarola Schellack, Karin Prinz, Alena Egyed, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 5, 2009
HFE C282Y mutation as a genetic modifier influencing disease susceptibility for chronic myeloproliferative diseaseHajnalka Andrikovics, Nora Meggyesi, Aniko Szilvasi, et al.
Pageof 36